Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Data access

Data access restrictions

Database access

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Syndications

Repository types

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 6 result(s)

Centers for Disease Control and Prevention, Data & Statistics

CDC

Subject(s)
Content type(s)
Country
CDC.gov is the Centers for Disease Control and Prevention primary online communication channel. CDC.gov provides users with credible, reliable health information on Data and Statistics, Diseases and Conditions, Emergencies and Disasters, Environmental Health, Healthy Living, Injury, Violence and Safety,Life Stages and Populations, Travelers' Health, Workplace Safety and Health

The Cancer Immunome Atlas

TCIA

Subject(s)
Content type(s)
Country
The Cancer Immunome Database (TCIA) provides results of comprehensive immunogenomic analyses of next generation sequencing data (NGS) data for 20 solid cancers from The Cancer Genome Atlas (TCGA) and other datasource. The Cancer Immunome Atlas (TCIA) was developed and is maintained at the Division of Bioinformatics (ICBI). The database can be queried for the gene expression of specific immune-related gene sets, cellular composition of immune infiltrates (characterized using gene set enrichment analyses and deconvolution), neoantigens and cancer-germline antigens, HLA types, and tumor heterogeneity (estimated from cancer cell fractions). Moreover it provides survival analyses for different types immunological parameters. TCIA will be constantly updated with new data and results.

CDC WONDER

Centers for Disease Control and Prevention, Wide-ranging OnLine Data for Epidemiologic Research

Subject(s)
Content type(s)
Country
CDC WONDER, developed by the Centers for Disease Control and Prevention (CDC), is an integrated information and communication system for public health. It allows you to access wide-ranging online data for epidemiologic research.

CancerModels.Org

formerly; Patients-derived tumor xenograft finder

Subject(s)
Content type(s)
Country
Patients-derived tumor xenograft (PDX) mouse models are an important oncology research platform to study tumor evolution, drug response and personalised medicine approaches. We have expanded to organoids and cell lines and are now called CancerModels.Org

45 and Up Study

Subject(s)
Content type(s)
Country
More than a quarter of a million people — one in 10 NSW men and women aged over 45 — have been recruited to our 45 and Up Study, the largest ongoing study of healthy ageing in the Southern Hemisphere. The baseline information collected from all of our participants is available in the Study’s Data Book. This information, which researchers use as the basis for their analyses, contains information on key variables such as height, weight, smoking status, family history of disease and levels of physical activity. By following such a large group of people over the long term, we are developing a world-class research resource that can be used to boost our understanding of how Australians are ageing. This will answer important health and quality-of-life questions and help manage and prevent illness through improved knowledge of conditions such as cancer, heart disease, depression, obesity and diabetes.

Androgen Receptor Mutations Database

AR Gene Mutations Database

Subject(s)
Content type(s)
Country
Androgen Receptor Gene Mutations Database is for all who are interested in mutations of the Androgen Receptor Gene. In light of the difficulty in getting new AR mutations published the curator will now accept new mutations that have not been published, provided that it is from a reputable research or clinical laboratory. The curator also strongly suggests that where possible, particularly in the case of new unique mutations that an attempt be made to at least confirm the pathogenicity of the putatative mutation, by showing that the mutation when transfected into a suitable expression system produces a mutant androgen receptor protein.